Chai Discovery
Funding History
| Seed · 09/2024 | $150M |
|---|---|
| Series B · 12/2025 | $1.3B |
| Series C · 07/2026 | $3.8B |
About
Chai Discovery's Chai-2 model was the first AI system to achieve double-digit experimental hit rates in fully de novo antibody design — roughly 100 times higher than prior computational methods — cutting typical discovery timelines from months to weeks.
- founded
- 2024
- headquarters
- San Francisco, CA
- totalFundingRaised
- $600M+
- latestValuation
- $3.8B
Overview
Chai Discovery is a San Francisco-based AI biology company, founded in 2024, that builds generative AI models for designing new proteins and antibodies from scratch. Its models — Chai-1, Chai-2, and Chai-3 — have been adopted by pharmaceutical partners including Eli Lilly, Pfizer, and Novartis to accelerate biologics discovery.
Founded by CEO Joshua Meier, President Jack Dent, and AI researchers Matthew McPartlon and Jacques Boitreaud, the company has raised over $600 million since its 2024 seed round, most recently closing a $400 million Series C at a $3.8 billion valuation in July 2026 — its third financing round in under a year.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.